Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment simplification strategies news

Show

From To
GSK takes on Gilead with new two-drug HIV treatments

GlaxoSmithKline is banking on new long-acting HIV medicines and simple two-drug regimens to close the gap on arch-rival Gilead Sciences.

Published
22 September 2015
From
Reuters
HIV Dual Therapy Matches Standard Triple Cocktail

A two-drug regimen (lopinavir/ritonavir plus lamivudine) for HIV did as well in controlling the virus as a standard triple-drug cocktail, researchers found. After 48 weeks of therapy with the dual-drug regimen, 88.3% of patients had undetectable virus.

Published
19 October 2013
From
MedPage Today
MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

In case you didn’t know, “MODERN” is the clever name for the “Maraviroc Once-daily with Darunavir Enhanced by Ritonavir in a New regimen” trial, which compared TDF/FTC to maraviroc, both with boosted darunavir. And once again, the NRTI-sparing two-drug regimen comes up short.

Published
17 October 2013
From
NEJM Journal Watch
PI monotherapy for HIV — an idea whose time has passed?

Patients who switched from suppressive triple-drug therapy to boosted protease-inhibitor monotherapy had unreasonably high rates of treatment failure.

Published
05 December 2012
From
Journal Watch
← Prev1234Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.